FDA Brief

Warning letters Drugs

FDA warning letter to

Monarch PCM, LLC

High riskIssued Jun 10, 2022Posted Jun 28, 2022Office of Pharmaceutical Quality Operations, Division II

Monarch PCM, LLC made unapproved skin drugs and broke manufacturing rules, with microbial contamination and weak investigations.

What happened

FDA inspected Monarch PCM's Fort Worth, Texas drug manufacturing facility from June 7 to August 20, 2021. Investigators found that the company failed to adequately investigate failed specification results, including Burkholderia cepacia complex (BCC) contamination in water and several aqueous drug products, and released some batches that did not meet specifications. FDA also found unsupported expiration dates, missing records, and that four prescription skin products were unapproved new drugs and two were not properly listed.

What FDA found

  1. The company did not thoroughly investigate out-of-specification results, including BCC contamination in water and products, and invalidated failures based on retests.

    21 CFR 211.192
  2. The company's water systems and manufacturing equipment were not properly designed, cleaned, or maintained, with repeated BCC, too-numerous-to-count, Staphylococcus aureus, and mold findings.

    21 CFR 211.63
  3. The quality control unit did not oversee manufacturing adequately: failing products were released, required BCC testing was skipped, reprocessing records were missing, and some CGMP records were missing.

    21 CFR 211.22
  4. The company's stability program did not support labeled expiration dates and did not include reprocessed batches, and some products failed assay or viscosity during stability.

    21 CFR 211.166(a)
  5. The company sold prescription skin products as new drugs without FDA-approved applications.

    FD&C Act 505(a) and 301(d) (21 U.S.C. 355(a), 331(d))
  6. Hydroquinone USP 4% Cream and Selenium Sulfide 2.25% Shampoo were not properly listed with FDA, including Monarch PCM as the manufacturing establishment and private label distributor listing requirements.

    FD&C Act 510(j); 21 CFR 207.49(12), 207.41(c)(2)

What FDA wants

FDA asks for comprehensive risk assessments, independent reviews, and corrective and preventive action (CAPA) plans for investigations, water and cleaning systems, the quality unit, and stability, plus BCC testing of retain samples of all within-expiry water-formulated batches within 30 days. It says to take rapid actions such as customer notifications and recalls if results or assessments show substandard quality.

Who should pay attention

  • brands that buy finished products from this contract manufacturer
  • companies selling prescription skin-care drugs
  • quality teams managing water systems and nonsterile manufacturing

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. CNC Noodle Corporation

    FDA warned CNC Noodle Corporation that its Hayward, California noodle plant had insanitary conditions, no pathogen or allergen controls, and mislabeled products.

    High risk
  2. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  3. Next Medical Products Company, LLC

    FDA warns Next Medical Products that its ultrasound gels were contaminated and made without required quality controls or clearance.

    High risk
  4. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk